In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

In another move designed to reduce the US' reliance on imported medicines, the FDA has launched a pilot of fast-track reviews for generics tested and made in domestic facilities. According to the ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

India’s weight-loss drug market is on the verge of a price shake-up. In days, domestic drugmakers are set to launch cheaper versions of semaglutide, the GLP-1 (glucagon-like peptide-1) therapy popular ...

The key component of Wegovy, which leads the global obesity treatment market, semaglutide, is losing patent protection in some countries. This lowers patent barriers in markets accounting for about 40 ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in the region has become impossible to ignore. While much of the immediate ...

As several Indian pharma giants race to launch cheaper generics for Semaglutide, the active ingredient in popular weight-loss drugs Ozempic and Wegovy, international brokerage Jefferies said that Sun ...

The Rasmussen Reports daily Presidential Tracking Poll for Friday shows that 45% of Likely U.S. Voters approve of President Trump’s job performance. Fifty-four (54%) disapprove. The latest figures ...